

# Aerogen<sup>®</sup>

## Clea:

Upper respiratory tract  
infection patient  
cared for with  
**high-flow**

Aerosolised medication can be effectively administered in-line via  
Aerogen<sup>1,2,3-7</sup> with no interruption to high-flow therapy<sup>1</sup>



### INTEGRATED AEROSOL DELIVERY

Aerogen fits in-line with  
no added flow and no  
interruption of therapy during  
administration of medication<sup>1</sup>



### EASE OF USE

Quick and easy to set up<sup>1</sup>  
with one system throughout  
a patient's respiratory journey  
(IMV, NIV, HF, SV)<sup>1</sup> supporting  
continuity of care



### EFFECTIVENESS

In-line aerosol drug delivery  
with Aerogen effectively  
delivers aerosol medication  
to the lungs during high-flow  
therapy<sup>1,2,3-7</sup>

## ...for healthy lungs

# Aerosol delivery during high-flow

The use of a conventional aerosol device can require a patient's high-flow therapy to be stopped while concomitant aerosol therapy is administered.<sup>18</sup>

With Aerogen, integrated aerosol delivery with high-flow is possible<sup>1,18</sup>

- Fits in-line with no added flow<sup>1</sup>
- No interruption of therapy during administration of medication<sup>1</sup>
- The circuit can be maintained during aerosol therapy<sup>1</sup>

## Ease of use

- Quick and easy to set up<sup>1</sup>
- Virtually silent,<sup>1</sup> keeping a calm environment for your patients
- In studies, in-line aerosol drug delivery was associated with better comfort<sup>18,99,510</sup> and improved convenience versus conventional aerosol therapy<sup>18</sup>

## Effectiveness



In studies, in-line aerosol drug delivery with Aerogen during high-flow was associated with:

- ~4x more medication delivered to the lungs (3.6%) versus a jet nebuliser (1.0%)<sup>12</sup>
- 3.5%–17% medication delivery to the lungs, depending on flow rates<sup>13</sup>
- Effective bronchodilator response, even with a gas flow of 50 L/min<sup>17</sup>

## Aerosol drug delivery in the COVID-19 era

Clinical and scientific societies around the world recommend the use of closed-circuit nebulisers like Aerogen for the management of patients with COVID-19 requiring aerosol drug delivery.<sup>11–17</sup>

- ✓ GOLD: 2023 Report<sup>11</sup>
- ✓ AARC: Guidance 2020<sup>12</sup>
- ✓ ISAM Interim Guidance 2020<sup>13</sup>



# Aerogen®

Clea is not based on a specific patient but are representative of common clinical situations.

<sup>1</sup>Study performed in healthy subjects. <sup>2</sup>Survey of worldwide clinical practice of HF and concomitant aerosol therapy in the adult ICU setting. Conventional aerosol therapy consisted of a vibrating mesh nebuliser, ultrasonic nebuliser or jet nebuliser used with a facemask. <sup>3</sup>A randomised, cross-over study in infants with bronchiolitis comparing in-line Aerogen vs jet nebuliser with a facemask. <sup>4</sup>At cumulative doses of 1.5–3.5 mg salbutamol in patients with COPD or asthma. <sup>5</sup>Representative images.

AARC, American Association for Respiratory Care; COPD, chronic obstructive respiratory disorder; HF, high-flow; ICU, intensive care unit; IMV, invasive mechanical ventilation; ISAM, International Society of Aerosols in Medicine; NIV, non-invasive ventilation; SV, self-ventilating.

1. 30-354 Rev U Aerogen Solo Instruction Manual. 2. Dugernier J, Hesse M, Jumetz T, et al. J Aerosol Med Pulm Drug Deliv. 2017;30(5):349-358. 3. Alcoforado L, Ari A, Barcelar JM, et al. Pharmaceutics. 2019;11(7):320. 4. Reminiac F, Vecellio L, Bodet-Contentin L, et al. Ann Intensive Care. 2018;8(1):128. 5. Li J, Zhao M, Hadeer M, et al. Respiration. 2019;98(5):401-409. 6. Beuvon C, Coudroy R, Bardin J, et al. Respir Care. 2021;respcare.09242. 7. Li J, Chen Y, Ehrmann S, et al. Pharmaceutics. 2021;13(10):1655. 8. Li J, Tu M, Yang L, et al. Respir Care. 2021;66(9):1416-1424. 9. Valencia-Ramos J, Miras A, Cilla A, et al. Respir Care. 2018;63(7):886-893. 10. Valencia-Ramos J, Ochoa Sangrador C, García M, et al. Arch Dis Child. 2022;107(12):1122-1127. 11. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: 2023 report. Available at: <https://goldcopd.org/2023-gold-report-2/> (accessed 06 December 2022). 12. American Association for Respiratory Care SARS-CoV-2 Guidance Document. Available at: <https://www.aarc.org/wp-content/uploads/2020/03/guidance-document-SARS-COVID19.pdf> (accessed 11 Nov 2022). 13. Fink JB, Ehrmann S, Li J, et al. J Aerosol Med Pulm Drug Deliv. 2020;33(6):300-304. 14. Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, et al. Med Intensiva (Engl Ed). 2020;44(7):429-438. 15. Respiratory care committee of Chinese Thoracic Society. Zhonghua Jie He He Hu Xi Za Zhi. 2020;17(0):E020. 16. Kumar S, Mehta S, Sarangdhar N, et al. Expert Rev Respir Med. 2021;15(4):519-535. 17. Swarnakar R, Gupta NM, Halder I, et al. Lung India. 2021;38(Supplement):S86-S91.